Merck's decision not to commercialize a successful CETP inhibitor trial drug was likely influenced by concerns about long-term tissue retention and potential legal liabilities.

Every Sunday: the week’s new conflicts and verdict changes — and nothing else.

Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.